drugset / Trial / NCT00930306

AZD2066 Cocktail Study

NCT00930306

Phase 1 Completed 15 enrolled AstraZeneca
RandomizedSingle-groupOpen-label

Summary

The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other

Timeline

Start
2009-06
Primary completion
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2066 Small molecule 8 mg Oral
Subject Caffeine Small molecule 100 mg Oral
Subject Midazolam Small molecule 7.5 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject Tolbutamide Small molecule 250 mg Oral

Indications